Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
Updated analyses report on progression-free survival, minimal residual disease negativity, overall response and overall survival across patient types, regardless of…